The Kids Research Institute Australia logo
Donate

Discover Prevent Cure

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome.

Citation:
Xiao L, Karsa M, Ronca E, Bongers A, ……… Cheung LC, Kotecha RS, Newbold A, et al. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Front Oncol. 2022;12

Keywords:
Chromatin; curaxin CBL0137; infant leukemia; mixed lineage leukemia protein; unclassified drug; acute lymphoblastic leukemia; acute lymphoid leukemia cell line; apoptosis; controlled study; RNA isolation

Abstract:
Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome.